Atara Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our corporate headquarters are located in Thousand Oaks, California (ARC) and consists of approximately 12,750 square feet of office, lab and warehouse space under a lease agreement that expires in February 2032.
The initial 10.5-year term of the ARC lease commenced in August 2021. In August 2025, we entered into an amendment to the ARC lease which reduced our square footage to 12,750 square feet and terminated our option to extend the lease.
In April 2022, we assigned our lease of approximately 90,580 square feet of office, lab and cellular therapy manufacturing space in Thousand Oaks, California, which expires in April 2033, to FDB as part of the Fujifilm Transaction. We remain joint and severally liable for obligations related to the assigned lease.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.